Quince Therapeutics, Inc.
Company Information
Industry
Biological Products, (No Diagnostic Substances)
SIC Code
2836
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
CA
Business Address
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO, CA, 94080
Mailing Address
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO, CA, 94080
Phone
415-910-5717
Fiscal Year End
1231
EIN
901024039
Financial Overview
FY2024
$167.90M
Total Assets
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 30, 2026 | View on SEC |
| 8-K Current report of material events | March 20, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | March 5, 2026 | View on SEC |
| 8-K Current report of material events | February 12, 2026 | View on SEC |
| 8-K Current report of material events | February 2, 2026 | View on SEC |
| 8-K Current report of material events | January 29, 2026 | View on SEC |
| 4 Insider stock transaction report | January 23, 2026 | View on SEC |
| 4 Insider stock transaction report | January 23, 2026 | View on SEC |
| 4 Insider stock transaction report | January 23, 2026 | View on SEC |
| 4 Insider stock transaction report | January 21, 2026 | View on SEC |
Material Events
8-K
Strategy Change
March 30, 2026
High Impact
- Debt reduction of $16.4 million settled for only $5.5 million
- Significant balance sheet cleanup removes restrictive covenants
8-K
Financial Distress
March 20, 2026
High Impact
- Company is actively considering options to regain Nasdaq compliance.
- Stock will continue trading on Nasdaq Global Select Market during the compliance period.
8-K
Strategy Change
January 29, 2026
High Impact
- Quince Therapeutics' lead drug candidate, eDSP, failed its Phase 3 clinical trial (NEAT) for Ataxia-Telangiectasia (A-T), not achieving primary or key secondary goals.
- The company has immediately halted all clinical development of eDSP.
Insider Trading
SELL
1 insiders
1 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2836)
Kodiak Sciences Inc.
KOD
Biological Products, (No Diagnostic Substances)
BioAtla, Inc.
BCAB
Biological Products, (No Diagnostic Substances)
Cardiff Oncology, Inc.
CRDF
Biological Products, (No Diagnostic Substances)
HALOZYME THERAPEUTICS, INC.
HALO
Biological Products, (No Diagnostic Substances)
Adaptive Biotechnologies Corp
ADPT
Biological Products, (No Diagnostic Substances)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.